

Daratumumab solution for injection and concentrate for solution for infusion (Darzalex®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2536	In combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/09/2023	31/12/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/daratumumab-darzalex-ndmm-full-smc2536/				
Mosunetuzumab concentrate for solution for infusion (Lunsumio®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2542	As monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.	Not routinely available as not recommended for use in NHS Scotland	20/09/2023	20/09/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/mosunetuzumab-lunsumio-full-smc2542/				

Ibrutinib film-coated tablets (Imbruvica®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2543	In combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/09/2023	31/12/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/ibrutinib-imbruvica-full-smc2543/				
Vutrisiran 25mg solution for injection in prefilled syringe (Amvuttra®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2596	For the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy	Available in line with national guidance	20/09/2023	20/09/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/vutrisiran-amvuttra-abb-smc2596/				

Rimegepant oral lyophilisate (Vydura®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2603	For the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month. SMC restriction: for patients with episodic migraine who have at least 4 migraine attacks per month, but fewer than 15 headache days per month and who have had prior failure on three or more migraine preventive treatments.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/09/2023	31/12/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/rimegepant-vydura-resub-smc2603/				
Nivolumab solution for infusion (Opdivo®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2620	In combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell programmed death ligand (PD-L1) expression \geq 1%.	Not routinely available as not recommended for use in NHS Scotland	20/09/2023	20/09/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-non-submission-smc2620/				

Crizotinib hard capsules (Xalkori®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2621	As monotherapy for the treatment of paediatric patients (age ≥6 to <18 years) with: <ul style="list-style-type: none"> relapsed or refractory systemic anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) recurrent or refractory anaplastic lymphoma kinase (ALK) positive unresectable inflammatory myofibroblastic tumour (IMT). 	Not routinely available as not recommended for use in NHS Scotland	20/09/2023	20/09/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/crizotinib-xalkori-non-submission-smc2621/				